Towards a Reference Case for Economic Evaluation of Osteoporosis Treatments

Journal of Rheumatology

Volumn 30, Issue SUPPL. 68, 2003, Pages 31-36

  Coyle, Douglas ^a,c   Tosteson, Anna N A ^b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; ECONOMIC ASPECT; FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MEDICAL RESEARCH; MORTALITY; OSTEOPOROSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE QUALITY; METHODOLOGY; PHARMACOECONOMICS; REVIEW; RHEUMATOLOGY; STANDARD; STATISTICAL MODEL;

ANTIRHEUMATIC AGENT;

ANTIRHEUMATIC AGENTS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; MODELS, ECONOMIC; OSTEOPOROSIS; PROGRAM EVALUATION; REFERENCE STANDARDS; RHEUMATOLOGY;

EID: 0347650291     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. CCOHTA Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa: CCOHTA; 1997.
2. Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee, including major submissions involving economic analyses. Canberra: Australian Govemment Publishing Press; 1995.
3. England and Wales Department of Health. Guidelines on good practice in the conduct of economic evaluation of medicines. London: Department of Health; 1994.
4. Ontario Ministry of Health. Ontario guidelines for economic analyses of pharmaceutical products. Toronto: Ministry of Health; 1994.
5. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996.
6. Maetzel A, Tugwell P, Boers M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003;30:891-6.
7. Papadimitropoulous EA, Coyte PC, Josse RG, Greenwood CE. Current and projected rates of hip fracture in Canada. CMAJ 1997;157:1357-63.
8. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 2000:15:721-39.
9. Coyle D, Buxton MJ, O'Brien BJ. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Health Economics 2003;12:421-7.
10. Coyle D, Lee KM. Evidence based economic evaluation: how different levels of data sources can impact results. In: Donaldson C, Mugford M, Vale L, editors. Evidence-based health economics: from effectiveness to efficiency in health care. London: BMJ Books; 2002.
11. Jacobsen SJ, Goldberg J, Miles TP, Brody JA, Stiers W, Rimm AA. Regional variation in the incidence of hip fracture: US white women aged 65 years and older. JAMA 1990;264:500-2.
12. Johnell O, Gullberg B, Allander JA, Kanis JA. The apparent incidence of hip fracture in Europe: A study of national register sources. Osteoporos Int 1992;2:298-302.
13. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991;324:1362-5.
14. Kassirer JP, Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med 1994;331:669-70.
15. Cranney A, Coyle D, Welch V, Lee K, Tugwell P. Current controversies in cost effectiveness analysis of osteoporosis therapies. J Rheumatol 1999;26:2300-2.
16. Tosteson AN, Jonsson B, Grima DT, O'Brien BJ, Black DM, Adachi JD. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 2001;12:849-57.
17. Zethreus N, Sendrine B, Caulin F, et al. Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 2003; 13:841-57.
18. Gabriel S. Controversies in economic evaluation in rheumatic diseases. J Rheumatol 1999;26:1859-60.
19. Goeree R, O'Brien B, Pettitt D, Cuddy L, Ferraz M,Adachi J. An assessment of the burden of illness due to osteoporosis in Canada. J SOGC 1996;Suppl: 15-22.
20. Melton LJ, Thamer M, Ray NF, et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12:16-23.
21. Coyle D, Cranney A, Lee KM, et al. Cost-effectiveness of nasal calcitonin in postmenopausal women. Pharmacoeconomics 2001;19:565-75.
22. Committee for Proprietary Medicinal Products. Note for guidance on postmenopausal osteoporosis in women. London: European Agency for the Evaluation of Medicinal Products; 2001.
23. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112:281-9.
24. WHO Collaborating Centre for Public Health Aspects of Osteoporosis and other Rheumatic Diseases. Recommendations for health economics evaluations of interventions in osteoporosis. Geneva: World Health Organization; 1999.
25. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ. Population-based study of survival after osteoporotic fracture. Am J Epidemiol 1993;137:1001-5.
26. Cree M, Soskolne CL, Belseck E, et al. Mortality and institutionalization following hip fracture. J Am Geriatr Soc 2000:48;283-8.
27. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999; 159:1215-20.
28. Leibson CL, Tosteson ANA, Gabriel SE, Ransom JE, Melton LJ III. Mortality, disability and nursing home use for persons with and without hip fracture: A population-based study. J Am Geriatr Soc 2002;50:1644-50.
29. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000;85:3109-15.
30. Kuntz K, Weinstein M. Modelling in economic evaluation. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press; 2001.
31. Tosteson ANA, Hammond CS, Grove MR, et al. Early osteoporosis treatment discontinuation among women with low bone mineral density. Am J Med 2003; (in press).
32. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.
33. Cranney A, Coyle D, Pham BA, et al. The psychometric propertiesm of patient preferences in osteoporosis. J Rheumatol 2001;28:132-7.
34. Tosteson ANA, Gabriel SE, Grove MR, et al. Impact of hip and vertebral fractures on quality adjusted life years. Osteoporos Int 2001;12:1042-9.
35. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989;5:559-75.
36. Tosteson ANA, Hammond CS. Quality-of-life assessment in osteoporosis: health-status and preference-based measures. Pharmacoeconomics 2002;20:289-303.
37. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index system for assessing health-related quality of life in clinical studies. Ann Med 2001;33:375-84.
38. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990; 16:199-208.
39. Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 2002; 13:768-76.
40. Gabriel SE, Kneeland TS, Melton LJ, Moncur MM, Ettinger B, Tosteson ANA. Health-related quality of life in economic evaluations for osteoporosis: Whose values should we use? Med Decis Making 1999; 19:141-8.
41. Briggs A, Goeree R, Blackhouse G, O'Brien B. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastro-esophageal reflux disease. Med Decis Making 2002;22:290-308.
42. Felli JC, Hazen GB. A Bayesian approach to sensitivity analysis. Health Economics 1999;8:263-8.
43. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985;5:157-77.
44. Thompson KM, Graham JD. Going beyond the single number: using probabilistic risk assessment to improve risk management. Hum Ecological Risk Assess 1996;2:1008-34.
45. Crystal ball. Version 5.1. Denver, CO: Decisioneering; 2000.
46. Data Pro. Williamstown, MA: Treeage Software.